Altered Blood Pressure Response to Propyldazine After Repeated Oral Administration in Conscious Normotensive Dogs: Role of the Renin-angiotensin System

Overview

Journal Basic Res Cardiol

Specialty Cardiology & Vascular Diseases

Date 1984 Sep 1

PMID 6391464

Authors

S Bacher

O KRAUPP

A Beck

R Seitelberger

G Raberger

Affiliations

Soon will be listed here.

Abstract

The magnitude and the persistence of blood pressure reduction by propyldazine (PDZ) was investigated following treatment over a period of 4 days. The experiments were performed on 6 normotensive dogs trained to submit to puncture of the femoral artery and to stand quietly in a special frame over the experimental period of 7 to 8 hours. The first dose effect of orally administered PDZ (0.06, 0.29 and 1.42 mg/kg) on heart rate, arterial blood pressure and plasma renin activity (PRA) was compared with the effect of the substance after treatment at the same respective dosage twice daily over 4 days. The compound caused a dose-dependent decrease in blood pressure accompanied by dose-dependent increases in heart rate and PRA. With 0.06 mg/kg and 0.29 mg/kg PDZ a sustained effect on arterial blood pressure was observed, whereas with 1.42 mg/kg PDZ tolerance occurred after treatment over the 4-day period. A comparison with the effects observed previously with 1.42 and 7.1 mg/kg dihydralazine (DHZ) under identical conditions showed similar results with respect to dose-dependence of blood pressure and counterregulation (1). It is considered that with a low-dose regimen there would be no decrease in activity of PDZ, the long-term hypotensive efficacy of the drug thereby being guaranteed.

References

Haber E, Koerner T, PAGE L, KLIMAN B, Purnode A . Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects. J Clin Endocrinol Metab. 1969; 29(10):1349-55. DOI: 10.1210/jcem-29-10-1349. View

Shepherd A, Lin M, Keeton T, MCNAY J . Plasma noradrenaline as a measure of baroreflex sensitivity in hypertensive man. Clin Sci (Lond). 1981; 61 Suppl 7:165s-168s. DOI: 10.1042/cs061165s. View

Packer M, Meller J, Medina N, Yushak M, Gorlin R . Determinants of drug response in severe chronic heart failure. 1. Activation of vasoconstrictor forces during vasodilator therapy. Circulation. 1981; 64(3):506-14. DOI: 10.1161/01.cir.64.3.506. View

Chatterjee K, Ports T, Brundage B, Massie B, Holly A, Parmley W . Oral hydralazine in chronic heart failure: sustained beneficial hemodynamic effects. Ann Intern Med. 1980; 92(5):600-4. DOI: 10.7326/0003-4819-92-5-600. View

Bacher S, KRAUPP O, Beck A, Seitelberger R, Raberger G . Blood pressure response and renin release following 4 days of treatment with dihydralazine and urapidil in conscious dogs. Cardiovasc Res. 1984; 18(2):67-74. DOI: 10.1093/cvr/18.2.67. View

Engler R, Pouleur H, Link J, Printz M, Covell J . Changes in control of renin release in congestive heart failure in dogs: response to acute and chronic vasodilator therapy. Clin Exp Hypertens A. 1982; 4(4-5):639-59. DOI: 10.3109/10641968209061604. View

DORIGOTTI L, Rolandi R, CARPI C . A new antihypertensive compound: 3 hydrazino-6- [(2-hydroxypropyl)methylamino] pyridazine dihydrochloride (ISF 2123). Pharmacol Res Commun. 1976; 8(3):295-308. DOI: 10.1016/0031-6989(76)90019-9. View

DORIGOTTI L, Semeraro C . Renal function studies with propildazine alone and in combination with propranolol in dogs. Eur J Pharmacol. 1980; 67(2-3):275-82. DOI: 10.1016/0014-2999(80)90508-7. View

Shepherd A, Ludden T, Haegele K, Talseth T, MCNAY J . Pharmacokinetics of hydralazine, apparent hydralazine and hydralazine pyruvic acid hydrazone in humans. Res Commun Chem Pathol Pharmacol. 1979; 26(1):129-44. View

10.

Reece P . Hydralazine and related compounds: chemistry, metabolism, and mode of action. Med Res Rev. 1981; 1(1):73-96. DOI: 10.1002/med.2610010105. View

11.

Franciosa J, Weber K, Levine T, Kinasewitz G, Janicki J, West J . Hydralazine in the long-term treatment of chronic heart failure: lack of difference from placebo. Am Heart J. 1982; 104(3):587-94. DOI: 10.1016/0002-8703(82)90231-9. View

12.

PIFFERI G, Parravicini F, CARPI C, DORIGOTTI L . Quinoxaline studies. 23. Potential antimalarials. Substituted 5,8-dimethoxy-6-[N-(omega-dimethylaminoalkyl)amino]quinoxalines were prepared: the first series with identical 2,3-substituents H, CH3, C6H5, C6H4-4-Cl, and CH2C6H5; and the second with.... J Med Chem. 1975; 18(7):741-6. DOI: 10.1021/jm00241a020. View

13.

Massingham R, HAYDEN M . A comparsion of the effects of prazosin and hydrallazine on blood pressure, heart rate and plasma renin activity in conscious renal hypertensive dogs. Eur J Pharmacol. 1975; 30(1):121-4. DOI: 10.1016/0014-2999(75)90213-7. View

14.

Higgins C, Vatner S, Eckberg D, Braunwald E . Alterations in the baroreceptor reflex in conscious dogs with heart failure. J Clin Invest. 1972; 51(4):715-24. PMC: 302183. DOI: 10.1172/JCI106865. View

15.

Gottlieb T, KATZ F, CHIDSEY 3rd C . Combined therapy with vasodilator drugs and beta-adrenergic blockade in hypertension. A comparative study of minoxidil and hydralazine. Circulation. 1972; 45(3):571-82. DOI: 10.1161/01.cir.45.3.571. View

16.

Elkayam U, Mathur M, Frishman W, Lejemtel T, Strom J, SONNENBLICK E . Dynamic responses to continuous use of prazosin and hydralazine in patients with refractory heart failure. Clin Pharmacol Ther. 1981; 30(1):23-30. DOI: 10.1038/clpt.1981.122. View

17.

OMalley K, Segal J, Israili Z, Boles M, MCNAY J, Dayton P . Duration of hydralazine action in hypertension. Clin Pharmacol Ther. 1975; 18(5 Pt 1):581-6. DOI: 10.1002/cpt1975185part1581. View

18.

PETTINGER W, Keeton K . Altered renin release and propranolol potentiation of vasodilatory drug hypotension. J Clin Invest. 1975; 55(2):236-43. PMC: 301742. DOI: 10.1172/JCI107927. View

19.

Worcel M . Relationship between the direct inhibitory effect of hydralazine and propildazine on arterial smooth muscle contractility and sympathetic innervation. J Pharmacol Exp Ther. 1978; 207(2):320-30. View

20.

Chidsey C, Braunwald E, Morrow A . CATECHOLAMINE EXCRETION AND CARDIAC STORES OF NOREPINEPHRINE IN CONGESTIVE HEART FAILURE. Am J Med. 1965; 39:442-51. DOI: 10.1016/0002-9343(65)90211-1. View